[ Diabetes Type 1 ]

current data and pharmacoepigenomic perspective, Pharmacogenomics, Future Medicine


Recently, the means by which specific antidiabetic drug classes might affect CVD risk has been examined. The aims were to measure the occurrence and attempt to assess the clinical significance of drug interactions involving antidiabetic agents. This study aims to fill this gap of research by conducting a Bayesian network meta-analysis to compare major antidiabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and SGLT-2 (sodium-glucose transporter-2) inhibitors. Data concerning adherence to drugs was assessed using measure treatment adherence scale (MTA). While it is generally considered a relatively safe drug, increased mortality associated with the use of metformin was reported during long [4] and even short-term follow-up [5]. The study published in The BMJ on Dec. 575-9.

The first included 8,494 patients after myocardial infarction in Denmark and found lower mortality rates for metformin than for SU users and risk appeared to be increased in men [40]. Metformin and sulfonylureas are often continued when once-daily insulin therapy has been commenced in the treatment of type 2 diabetes. Knowledge of the list of institutes that belong to community 2, and with the help of the co-authorship network, the researcher could select the most appropriate expert for research collaboration based on centrality measurements.

Tags: , ,